TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03825445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHa (Fertipeptil 0.1mg)
Description: Two doses of GnRH-a (Fertipeptil 0.1mg x 2 vial) for ovulation trigger after ovarian stimulation for IUI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG (Pregnyl 5000IU)
Description: hCG (Pregnyl 5000IU) for ovulation trigger after ovarian stimulation for IUI.
Study: NCT01832974

Intervention type: DRUG
Group type: OTHER
Intervention: IL-13-PE
Description: IL-13-PE intravenous infusion
Study: NCT02171949

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of bone marrow mononuclear cells.
Description: Patients on this group will receive therapy with mononuclear cells. The cells will be diluted on saline and then injected on the hepatic artery through femoral artery puncture.
Study: NCT04016987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated structured education intervention based on an app and artificial intelligence
Description: In the 24-week intervention period, the experimental group receives automated push notifications supported by artificial intelligent algorithm.
Study: NCT01809197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lenses
Description: Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon A contact lenses
Description: Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS)
Description: Multi-purpose disinfecting solution for contact lens care, used per manufacturer's instructions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Multi-Purpose Solution (MPS)
Description: Multi-purpose solution for contact lens care according to subject's habitual brand, used per manufacturer's instructions
Study: NCT01832974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-13-PE
Description: IL-13-PE intravenous infusion
Study: NCT02433730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: intramuscular injection
Study: NCT02680080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: a single 400 mg tablet of Moxifloxacin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grapefruit group
Description: one liter of fresh pink-grapefruit juice
Study: NCT02730429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib/placebo
Description: Palbociclib or a placebo is administered together with standard of care letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole is standard of care in both arms
Study: NCT00901589

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: marine n-3 polyunsaturated fatty acids
Description: Four capsules daily containing 2.2 g marine n-3 polyunsaturated fatty acids in total
Study: NCT02730429

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Letrozole is standard of care in both arms
Study: NCT03147261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Intensive changes in lifestyle with a reduced calorie mediterranean diet, physical activity and behavioral therapy
Study: NCT01370356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline Tartrate
Description: Varenicline Tartrate oral tablets 2 (0.5mg) tablets twice a day for 24 weeks (first week titration)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo 2 oral tablets twice a day for 24 weeks (first week titration)
Study: NCT04284670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE
Description: The intervention group will perform an 8 week program, 2 sessions a weak for a total of 16 sessions. training will be done on a designated negative gradient treadmill, first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXERCISE
Description: The intervention group will perform an 8 week program, 2 sessions a weak for a total of 16 sessions. training will be done on a designated negative gradient treadmill, first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.
Study: NCT03197597

Intervention type: OTHER
Intervention: Strain isolation from the nasopharynx
Description: B. pertussis strains has been collected from the nasopharynx of the patients during the clinical visit
Study: NCT02446483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idiazole 20mg DR tabs
Description: Delayed release tablets containing 20 mg of rabeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idiazole 20mg DR tabs
Description: Delayed release tablets containing 20 mg of rabeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARIET 20 mg DR tabs
Description: Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARIET 20 mg DR tabs
Description: Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
Study: NCT03208244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clinically prescribed direct acting antiviral
Description: HCV treatment for 12 weeks
Study: NCT00901589

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: thistle oil
Description: four capsules a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: marine n-3 polyunsaturated fatty acids
Description: Four capsules daily, 2.2 g marine n-3 PUFAs in total

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Thistle oil
Description: Four capsules daily
Study: NCT01819441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelnidipine
Description: 8mg or 16mg

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Azelnidipine
Description: 8mg or 16mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril
Description: 4mg or 8mg
Study: NCT02398175

Intervention type: OTHER
Intervention: reanimation/intubation
Study: NCT04531943

Intervention type: DRUG
Intervention: Estrogen
Description: Feminizing hormone therapy consisting of estrogen alone, as prescribed by the participant's healthcare provider.

Intervention type: DRUG
Intervention: Estrogen
Description: Feminizing hormone therapy consisting of estrogen alone, as prescribed by the participant's healthcare provider.

Intervention type: DRUG
Intervention: Estrogen plus Progesterone
Description: Feminizing hormone therapy consisting of estrogen and progesterone, as prescribed by the participant's healthcare provider.

Intervention type: DRUG
Intervention: Estrogen plus Progesterone
Description: Feminizing hormone therapy consisting of estrogen and progesterone, as prescribed by the participant's healthcare provider.
Study: NCT04999176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with oral rivaroxaban (10 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with subcutaneous enoxaparin (40 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.
Study: NCT02941991

Intervention type: BIOLOGICAL
Intervention: hESC-RPE
Description: sub-retinal injection
Study: NCT00654680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil (Levitra, BAY38-9456)
Description: 5mg, 10mg or 20mg taken 1 hour prior to sexual intercourse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01819441

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Perindopril
Description: 4mg or 8mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide
Description: 12.5mg or 25mg

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: hydrochlorothiazide
Description: 12.5mg or 25mg
Study: NCT01510223

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 90 g olive oil added to the supplement for the purpose of the HF intervention phase.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil and fish powder
Description: Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 86.67 g olive oil and 3.3 g of n-3 fish powder (500 mg EPA+DHA)added to the supplement for the purpose of the HF intervention phase.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil and macadamia oil
Description: Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 74.82 g olive oil and 15.18 g macadamia nut oil added to the supplement for the purpose of the HF intervention phase.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Deadaptation
Description: A period of 5 days supplementation with the low-fat milkshake represents a de-adaptation period from high-fat intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Deadaptation
Description: A period of 5 days supplementation with the low-fat milkshake represents a de-adaptation period from high-fat intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Deadaptation
Description: A period of 5 days supplementation with the low-fat milkshake represents a de-adaptation period from high-fat intervention.
Study: NCT00010803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo biloba
Description: 120mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One pill twice daily
Study: NCT01415908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFUSE Bone Graft
Description: Subjects enrolled in the investigational treatment group will receive surgical treatment with INFUSE® Bone Graft, the CAPSTONE® Spinal System, and posterior supplemental fixation (in this study the CD HORIZON® Spinal System). The investigational treatment will be implanted using a TLIF surgical approach.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iliac Crest Bone Graft
Description: Subjects enrolled in the control group will receive the same surgical treatment as the investigational group, including the CAPSTONE® Spinal System and posterior supplemental fixation system (CD HORIZON® Spinal System), except for the use of autogenous bone graft (from the iliac crest) instead of INFUSE® Bone Graft. A TLIF surgical approach will also be used for implanting the control treatment.
Study: NCT00650312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride ER Tablets 500 mg
Description: 500mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR Tablets 500 mg
Description: 500mg, single dose fasting
Study: NCT04456595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adsorbed COVID-19 (inactivated) Vaccine
Description: Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adsorbed COVID-19 (inactivated) Vaccine
Description: Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
Study: NCT02485613

Intervention type: DRUG
Intervention: bortezominb and dexamethasone
Description: The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). The dose of bortezomib and dexamethasone can be adjusted according to the patients' condition.
Study: NCT04111653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mud therapy
Description: Application of sludge poultice
Study: NCT04208880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TBH Brain Workout 1.0
Description: TBH Brain Workout program with easy challenge activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health Book Club
Description: Each week a new chapter will be read that contains new information to enhance brain health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TBH Brain Workout 2.0
Description: TBH Brain Workout program with moderately difficult challenge activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TBH Memory 1.0
Description: TBH Memory program with easy challenge activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TBH Memory 2.0
Description: TBH Memory program with moderately difficult challenge activities
Study: NCT02794025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava. The initial dose was 0.05 mg/kg/min and was adjusted based on heart rate (HR) (target HR: 70 bpm \< HR \< 100 bpm within 72 hours).~Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: natural saline
Description: Control group also received natural saline via a micro pump,
Study: NCT01733836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03022513

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten free diet
Description: The investigators will evaluate the prevalence of fibromyalgia-like joint/muscle pain and the possible ultrasonographical alterations (i.e. synovitis) of hands and feet joints in NCWS patient at baseline (i.e. at the moment of diagnosis) and after a gluten free diet period of almost 6 months.
Study: NCT02537223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT)
Study: NCT02844673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Directly Observed Therapy
Description: Mobile DOT will consist of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Patients will receive alerts on their cell phone at pre-arranged times to remind them to take their medications.
Study: NCT02244229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03771495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: Manual Therapy Intervention, commonly used by physiotherapists

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Laying on of Hands
Description: Sham Hip Joint Mobilization
Study: NCT00778310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate-OROS
Description: The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of Concerta that are made to appear similar to placebo capsules. The subject will be administered their usual dose of Concerta the morning of the scan.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of placebo that are made to appear similar to Concerta capsules. The subject will be administered placebo the morning of the scan.
Study: NCT02597192

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: probiotic oral hygiene products with Bacillus (PIP, Chrisal)
Description: products with Bacillus probiotics

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral hygiene products without Bacillus
Description: products without Bacillus
Study: NCT00643448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: AZD1305 loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: AZD1305 loading dose 500 mg + placebo evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo corresponding to AZD1305 loading dose + evening dose on Study Day 1, maintenance dose twice daily from Study Day 2
Study: NCT02176980

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief alcohol counseling
Description: Medical provider gives feedback on how the patient's alcohol use may affect their current and future health, noting that it is the patient's responsibility to change behavior; giving advice to stop drinking based on medical concern; giving a menu of options for cutting down on drinking; expressing empathy; and reinforcing the patient's self-efficacy to change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group and Individual Therapy Sessions
Description: Session content integrates HCV and alcohol issues in treatment, liver health, and personal realms. Sessions include psychoeducational content on how alcohol affects the liver among people with HCV; HCV stigma; family issues around drinking and the HCV diagnosis; nutrition; life goals and positive affect; and alcohol reduction strategies.
Study: NCT03127436

Intervention type: DRUG
Intervention: Acarovac
Description: House dust mite sensitized Patients receive increasing doses of subcutaneous immunotherapy with Acarovac. During the up-dosing phase, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.
Study: NCT02786836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13C-Methacetin
Description: The test substrate in this study, ¹³C-methacetin solution for single-use oral administration (75 mg in 150 ml purified water), is administered orally or via feeding tube, rapidly absorbed, exclusively metabolized by hepatic mixed function oxidase via O-demethylation, mainly by cytochrome P450 enzyme, subtype 1A2, into acetaminophen and formaldehyde. The formaldehyde is then transformed through two successive oxidative steps to ¹³carbon dioxide, the quantity of which is measured in exhaled breath as a ratio of 13C to 12C.~The nasal or intubated breath sampling investigational device (ID) circuit continuously transports the breath sample from the patient to the BreathID® MCS device before and following administration of the 13C-methylacetanilide test substrate.